$MRK Merck & Co Q2 Earnings

04 Aug 2026 10:33MRK
  • Adj. loss/shr $0.13, est. loss/shr $0.23
  • Loss/shr $0.54
  • Sales $16.61B, est. $16.35B
  • Keytruda rev. $8.37B, +5.2% y/y, est. $8.04B
  • Gardasil rev. $1.17B, est. $1.12B
  • Animal health sales $1.78B, est. $1.75B
  • Adj. gross margin about 81%, saw about 82%
  • YR adj. EPS view incl. $9B charges tied to Cidara deal
  • YR adj. EPS view incl. $5.7B charges for Terns deal
  • Sees FY adj. EPS $2.66 to $2.76, saw $5.04 to $5.16
  • Sees FY sales $66.3B to $67.3B, saw $65.8B to $67B
  • Boosts FY sales forecast